Evotec and co-investors support Dutch Facio Therapies BV with 4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy.
With its investement alongside unnamed Australian and North American investors, Evotec enters the field of musculoskeletal diseases.
Currently there is no causative treatment for the muscle wasting disease that affects 700,000 people worldwide. In a patient cell-based screening, Evotec and Facio Therapies (Leiden) have already identified some FSHD candidate drugs, which block the overexpression of the DUX4 protein in skeletal muscle cells that causes muscle atrophy and oxidative stress, hallmarks of the disease. About 20% of people with FSHD end up in a wheelchair.
Facio announced it will use the proceeds to select pre-clinical lead candidates for further development. According to the NIH, the field of muscular dystrophies received US$80m in funding in 2017. One tenth of the amount has been channeled into FSHD research.
Some companies have already started clinical testing of candidate drugs for treating FSHD. aTyr Pharma, Inc. is in Phase I/IIa testing of the protein drug Resolaris in early onset FSHD. Acceleron Pharma, Inc. has recently started Phase II testing of ACE083, an inhibitor of proteins of the TGF-beta family.
Read the original post:
Evotec invests in Facio Therapies - European Biotechnology - European Biotechnology
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022
- Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -59.36% This Week? - InvestorsObserver - November 17th, 2022
- Should Biotechnology Stock LogicBio Therapeutics Inc (LOGC) Be in Your Portfolio Tuesday? - InvestorsObserver - November 17th, 2022
- PDS BIOTECHNOLOGY CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.com - November 17th, 2022
- Biotechnology Industrial Training Program Winter Edition By Startup Incubation and Innovation Centre IIT Kanpur - BioTecNika - November 17th, 2022
- Where Does Axsome Therapeutics Inc (AXSM) Stock Fall in the Biotechnology Field After It Is Lower By -1.80% This Week? - InvestorsObserver - November 17th, 2022
- Where Does CTI BioPharma Corp (CTIC) Stock Fall in the Biotechnology Field After It Is Higher By 3.33% This Week? - InvestorsObserver - November 7th, 2022
- VIR BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - November 7th, 2022
- Is Syndax Pharmaceuticals Inc (SNDX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 7th, 2022
- An Introduction to Biotechnology - PMC - PubMed Central (PMC) - October 31st, 2022
- Biotechnology, M.S. | Florida Tech - FIT - October 31st, 2022
- What is Biotech? Types of Biotech + More | Built In - October 31st, 2022
- Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022... - October 31st, 2022
- Where Does Sorrento Therapeutics Inc (SRNE) Stock Fall in the Biotechnology Field After It Is Up 6.58% This Week? - InvestorsObserver - October 31st, 2022
- Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Lower By -5.84% This Week? - InvestorsObserver - October 31st, 2022
- Zero emission vehicles: first Fit for 55 deal will end the sale of new CO2 emitting cars in Europ... - Modern Diplomacy - October 31st, 2022
- The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 - ResearchAndMarkets.com - Business Wire - September 29th, 2022
- Argentina: Promotion of modern biotechnology and nanotechnology - Lexology - September 29th, 2022
- Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors - GlobeNewswire - September 29th, 2022
- CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept - September 29th, 2022
- Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis... - September 29th, 2022
- Viewpoint: Will King Charles abandon his kooky ideas about agriculture and help accelerate Britain's embrace of sustainable biotechnology tools? -... - September 29th, 2022
- Top Biotechnology Stocks to Buy in 2022 - Best Stocks - September 29th, 2022
- Biotechnology investing for the social good making money and a difference - Stockhead - September 29th, 2022
- Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit - GlobeNewswire - September 29th, 2022
- Fact Sheet - HHS.gov - September 20th, 2022
- Deputy Secretary of Defense Dr. Kathleen Hicks' Remarks at the White House Summit on Biote - Department of Defense - September 20th, 2022